- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Prescient Therapeutics Ltd (ASX:PTX) has entered into a five-year manufacturing services agreement with specialist cell therapy...
Prescient Therapeutics signs deal with Q-Gen to enable OmniCAR clinical trials
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion...
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be...
Prescient (ASX: PTX) makes ‘solid progress on all fronts’ in June quarter
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
ASX Quarterlies: From fintech to biotech, these small caps have delivered strong performances for shareholders
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
Prescient Therapeutics (ASX:PTX) advances clinical programs in June quarter
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over...
Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...
Prescient first in class cancer drug PTX-100 granted Orphan Drug status by the US FDA
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...